Literature DB >> 17433504

Activation of glycogen synthase kinase-3 inhibits protein phosphatase-2A and the underlying mechanisms.

Gong-Ping Liu1, Yao Zhang, Xiu-Qing Yao, Chang-E Zhang, Jiang Fang, Qun Wang, Jian-Zhi Wang.   

Abstract

The activity of protein phosphatase-2A (PP-2A) is significantly suppressed in the brain of Alzheimer's disease (AD) patients, but the mechanism is not understood. Here, we found an in vivo association of glycogen synthase kinase 3beta (GSK-3beta) with inhibitor-2 of PP-2A (I(2)(PP-2A)). The activation of GSK-3 resulted in accumulation of I(2)(PP-2A) with concomitant suppression of PP-2A activity and increases of tau phosphorylation in HEK293, N2a and PC12 cells, while inhibition of GSK-3 caused decreases of I(2)(PP-2A) with increased PP-2A activity and decreased tau phosphorylation. A positive correlation between GSK-3beta and I(2)(PP-2A) (R=0.9158) and a negative correlation between GSK-3beta and PP-2A (R=-0.9166) were detected. GSK-3 activation did not affect I(2)(PP-2A) mRNA level, while it increased the mRNA level of a heterogeneous ribonucleoprotein A18 (hnRNP A18). The activation of GSK-3 increased the expression and the activity of proteasome system. It suggests that activation of GSK-3 inhibits PP-2A through up-regulation of I(2)(PP-2A) with hnRNP A18-involved mechanism.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17433504     DOI: 10.1016/j.neurobiolaging.2007.03.012

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  27 in total

1.  MAPT/Tau accumulation represses autophagy flux by disrupting IST1-regulated ESCRT-III complex formation: a vicious cycle in Alzheimer neurodegeneration.

Authors:  Qiong Feng; Yu Luo; Xiang-Nan Zhang; Xi-Fei Yang; Xiao-Yue Hong; Dong-Shen Sun; Xia-Chun Li; Yu Hu; Xiao-Guang Li; Jun-Fei Zhang; Xiao Li; Ying Yang; Qun Wang; Gong-Ping Liu; Jian-Zhi Wang
Journal:  Autophagy       Date:  2019-06-28       Impact factor: 16.016

Review 2.  RNA regulons are essential in intestinal homeostasis.

Authors:  Louis R Parham; Patrick A Williams; Priya Chatterji; Kelly A Whelan; Kathryn E Hamilton
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2018-12-06       Impact factor: 4.052

3.  Mechanism of inhibition of PP2A activity and abnormal hyperphosphorylation of tau by I2(PP2A)/SET.

Authors:  Lisette Arnaud; She Chen; Fei Liu; Bin Li; Sabiha Khatoon; Inge Grundke-Iqbal; Khalid Iqbal
Journal:  FEBS Lett       Date:  2011-07-28       Impact factor: 4.124

4.  Cytoplasmic retention of protein phosphatase 2A inhibitor 2 (I2PP2A) induces Alzheimer-like abnormal hyperphosphorylation of Tau.

Authors:  Mohammad Arif; Jianshe Wei; Qi Zhang; Fei Liu; Gustavo Basurto-Islas; Inge Grundke-Iqbal; Khalid Iqbal
Journal:  J Biol Chem       Date:  2014-08-15       Impact factor: 5.157

Review 5.  Tau-induced neurodegeneration: mechanisms and targets.

Authors:  Cindy Beharry; Leah S Cohen; Jing Di; Kawsar Ibrahim; Susan Briffa-Mirabella; Alejandra del C Alonso
Journal:  Neurosci Bull       Date:  2014-04-15       Impact factor: 5.203

6.  Protective effects of humanin on okadaic Acid-induced neurotoxicities in cultured cortical neurons.

Authors:  Jinfeng Zhao; Dan Wang; Lingmin Li; Wenhui Zhao; Ce Zhang
Journal:  Neurochem Res       Date:  2014-08-21       Impact factor: 3.996

Review 7.  Extracellular CIRP (eCIRP) and inflammation.

Authors:  Monowar Aziz; Max Brenner; Ping Wang
Journal:  J Leukoc Biol       Date:  2019-01-15       Impact factor: 4.962

8.  Parkin attenuates wild-type tau modification in the presence of beta-amyloid and alpha-synuclein.

Authors:  Charbel E-H Moussa
Journal:  J Mol Neurosci       Date:  2008-06-17       Impact factor: 3.444

9.  Ceramide signaling in cancer and stem cells.

Authors:  Erhard Bieberich
Journal:  Future Lipidol       Date:  2008-06

10.  Estradiol attenuates tau hyperphosphorylation induced by upregulation of protein kinase-A.

Authors:  Xin-An Liu; Ling-Qiang Zhu; Qi Zhang; Hai-Rong Shi; Shao-Hui Wang; Qun Wang; Jian-Zhi Wang
Journal:  Neurochem Res       Date:  2008-03-13       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.